Disease characteristics
| Characteristic . | N = 152 . |
|---|---|
| FLT3-ITD∗ | 134 (88%) |
| FLT3-TKD∗ | 23 (16%) |
| Evolution of FLT3 mutation | |
| Present at diagnosis and relapse | 131 (86%) |
| Emergent upon relapse | 21 (14%) |
| Cytogenetic/FISH abnormalities | |
| Normal karyotype | 89 (62%) |
| +8 | 16 (11%) |
| KMT2A rearrangement | 4 (2.7%) |
| MECOM rearrangement | 3 (2.1%) |
| Complex karyotype | 5 (3.5%) |
| Other adverse, noncomplex (del5q, −7, del17p) | 8 (5.6%) |
| Failed or missing | 6 |
| MRC cytogenetic risk | |
| Intermediate | 134 (88%) |
| Adverse | 18 (12%) |
| NPM1 mutation | 52 (34%) |
| Molecular mutations (present in >5%) | |
| DNMT3A | 44 (35%) |
| RUNX1 | 25 (20%) |
| TET2 | 15 (12%) |
| SRSF2 | 13 (10%) |
| IDH2 | 13 (10%) |
| ASXL1 | 12 (9.6%) |
| WT1 | 12 (9.6%) |
| NRAS | 10 (8.0%) |
| SF3B1 | 9 (7.2%) |
| IDH1 | 8 (6.4%) |
| Missing | 27 |
| ELN 2022 risk classification | |
| Favorable | 5 (3.3%) |
| Intermediate | 96 (64%) |
| Adverse | 50 (33%) |
| Characteristic . | N = 152 . |
|---|---|
| FLT3-ITD∗ | 134 (88%) |
| FLT3-TKD∗ | 23 (16%) |
| Evolution of FLT3 mutation | |
| Present at diagnosis and relapse | 131 (86%) |
| Emergent upon relapse | 21 (14%) |
| Cytogenetic/FISH abnormalities | |
| Normal karyotype | 89 (62%) |
| +8 | 16 (11%) |
| KMT2A rearrangement | 4 (2.7%) |
| MECOM rearrangement | 3 (2.1%) |
| Complex karyotype | 5 (3.5%) |
| Other adverse, noncomplex (del5q, −7, del17p) | 8 (5.6%) |
| Failed or missing | 6 |
| MRC cytogenetic risk | |
| Intermediate | 134 (88%) |
| Adverse | 18 (12%) |
| NPM1 mutation | 52 (34%) |
| Molecular mutations (present in >5%) | |
| DNMT3A | 44 (35%) |
| RUNX1 | 25 (20%) |
| TET2 | 15 (12%) |
| SRSF2 | 13 (10%) |
| IDH2 | 13 (10%) |
| ASXL1 | 12 (9.6%) |
| WT1 | 12 (9.6%) |
| NRAS | 10 (8.0%) |
| SF3B1 | 9 (7.2%) |
| IDH1 | 8 (6.4%) |
| Missing | 27 |
| ELN 2022 risk classification | |
| Favorable | 5 (3.3%) |
| Intermediate | 96 (64%) |
| Adverse | 50 (33%) |
FISH, fluorescence in situ hybridization; MRC, Medical Research Council.
Five patients had both FLT3-ITD and FLT3-TKD